A take-home message of the PRAMI trial for interventionalists

  • September 2, 2013

AMSTERDAM — George Vetrovec, MD, a member of the Cardiology Today Editorial Board, provides expert perspective on the PRAMI trial, which suggested that preventive PCI in noninfarct coronary arteries of patients with STEMI and multivessel disease may play a role in reducing the risk for adverse CV events.

He discusses the longstanding debate surrounding what to do with nonacute lesions in the setting of acute MI, what the new PRAMI data add to the current knowledge base and questions that can be raised moving forward.


Healio is intended for health care provider use and all comments will be posted at the discretion of the editors. We reserve the right not to post any comments with unsolicited information about medical devices or other products. At no time will Healio be used for medical advice to patients.